title: [Treatment with nebulized lidocaine in steroid-dependent asthma].
abstract: BACKGROUND
  The management of glucocorticoid dependent and resistant asthma encompasses a group of problems, affecting as much control of clinical symptoms as the onset of adverse effects to prolonged use of steroids.
  
  
  METHODS
  Woman 52 years old, steroid dependent asthma fifteen years ago. She has important adverse effects in consequence of the use of systemic glucocorticoids. The employment of methotrexate attained decrease in the dosage of steroids temporarily. The worsening of the clinical situation and deterioration of secondary effects by use of steroids necessitated treatment with nebulized lidocaine. A 2% solution to initial dosage was administered three times daily. The maximal dosage needed was 80 mg three times daily.
  
  
  RESULTS
  After three months of lidocaine treatment, the patient was able to reduce oral steroids eventually discontinuing these drugs, and the effects secondary to exogenous hypercortisolism disappeared. Moreover, an improvement in clinical symptoms and quality of life was observed with stability in the pulmonary function.
  
  
  CONCLUSIONS
  The use of nebulized lidocaine could be useful and provide alternatives in patients with severe asthma.
authors.affiliation: Unidad de Alergia, Hospital Santa Bárbara, Complejo Hospitalario de Soria, Spain. alerspa@hotmail.com
authors.forename: S
authors.initials: S
authors.lastname: de Paz Arranz
authors.forename: M
authors.initials: M
authors.lastname: Rodríguez Mosquera
authors.forename: B
authors.initials: B
authors.lastname: Fernández Parra
authors.forename: M
authors.initials: M
authors.lastname: Santaolalla Montoya
authors.forename: I
authors.initials: I
authors.lastname: Herrera Mozo
authors.forename: A
authors.initials: A
authors.lastname: Pérez Pimiento
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000336:Aerosols; D001249:Asthma / Q000188:drug therapy*; D004802:Eosinophilia / Q000188:drug therapy* / Q000209:etiology; D004804:Eosinophils / Q000187:drug effects; D005260:Female; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011282:Pregnenediones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D019966:Substance-Related Disorders
chemical_list: D000305:Adrenal Cortex Hormones; D000319:Adrenergic beta-Antagonists; D000336:Aerosols; D011282:Pregnenediones; D008012:Lidocaine; C021988:deflazacort; D011241:Prednisone; D008775:Methylprednisolone